Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 150 of 185 publications.

Harris DH, Gilsenan AW, Midkiff KD, Harding AA. Navigating the registry-specific approval process for a long-term drug safety surveillance study. Presented at the NAACCR - North American Association of Central Cancer Registries; June 2013.

Midkiff KD, Harris DH, Gilsenan AW, Powell GL. Variations among cancer registries in accessing patients for a drug safety surveillance study. Poster presented at the NAACCR; June 2013.

Gilsenan AW, Andrews EB. Considerations and strategies for benefit-risk assessment in the real-world setting. In: Sashegyi A, Felli J, Noel R, editors. Benefit-risk assessment in pharmaceutical research and development. 1st ed. Boca Raton: United States. CRC Press; 2013. p.153-64.

Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Massica D. Seeing the big picture in long-term surveillance for rare events. Presented at the North American Association of Central Cancer Registries Annual Conference; 2013.

Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768

Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324

Harris DH, Gilsenan AW, Wu Y, Andrews EB. Using cancer surveillance data to advance science: monitoring for a potential safety signal for approved drugs through linkage studies. Poster presented at the Annual Meeting of the North American Association of Central Cancer Registries; 2012.

Chirila C, Gilligan TM, Gilsenan A, Price M, Hollis K, Calingaert B, Zografos L, Andrews E. A comparison of factors influencing patient knowledge: results across selected REMS surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Gilsenan A, Hollis K, Zografos L, Calingaert B, Andrews E. Examination of respondent bias and patient characteristics in multiple REMS assessment surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Gilsenan A, Harris DH, Midkiff K, Wright J, Andrews E. Linking with multiple state cancer registries for safety surveillance study – Is it feasible? Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Midkiff KD, Harris D, Gilsenan AW, Wu Y, Andrews EB. Drug safety studies using cancer registry data: confluence of elements impacting the interview response rate. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 14, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 1; 20(Suppl. 1):S231. doi: 10.1002/pds.2206

Midkiff KD, Gilsenan AW, Wu Y, Harris DH, Masica D, Andrews EB. Using cancer registry data to advance the science of drug safety: results from an ongoing postmarketing drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Conference; June 21, 2011. Lexington, KY.

Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grellet CA, Gilsenan AW, McLeod LD, Dalal AA, Raphiou IH, Prillaman BA, Crater GD, Cicale MJ, Mapel DW. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May 1;86(5):375-81.

Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, Coplan PM, Mussen F. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011 Feb 1;89(2):217-24. doi: 10.1038/clpt.2010.280

Andrews EB, Midkiff KD, Gilsenan AW, Harris DH. Collaboration with multiple state cancer registries for a data linkage drug safety surveillance study – yes you can!. Poster presented at the North American Association of Central Cancer Registries Annual Conference; 2011.

Gilsenan AW, Midkiff KD, Harris DH. Opportunities for improving the use of cancer registry data in drug safety studies: factors influencing interview response rate. Presented at the North American Association of Central Cancer Registries Annual Conference; 2011.

Midkiff KD, Gilsenan AW, Harris DH, Wu Y, Masica D, Andrews EB. Exposure to possible osteosarcoma risk factors in a US postmarketing osteosarcoma surveillance study. Poster presented at the Scandinavian Sarcoma Group Annual Meeting; 2011.

Midkiff K, Gilsenan A, Wu Y, Masica D, Andrews E. Characteristics of adult osteosarcoma patients: results from an ongoing post-marketing drug safety surveillance study. Poster presented at the American Society of Clinical Oncology; August 30, 2010.

Gilsenan A, Andrews E, Hollis KA. Characterization of current risk evaluation and mitigation strategies. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(S1):S100. doi: 10.1002/pds.2019

Liu AH, Gilsenan AW, Stanford RH, Lincourt W, Ziemiecki R, Ortega H. Status of asthma control in pediatric primary care: results from the pediatric asthma control characteristics and prevalence survey study (access). J Pediatr. 2010 Aug 1;157(2):276-U135.

Gilsenan AW, Andrews EB, Midkiff KD, Ladner A. Charting a new course in long-term safety: the critical role of cancer registries. Poster presented at the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2010. Brighton, United Kingdom. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(Suppl 1):S116.

Harris DH, Midkiff KD, Gilsenan AW, Andrews EB. Public health surveillance collaboration: establishing a linkage algorithm with cancer registries for the Forteo Patient Registry. Poster presented at the North American Association of Central Cancer Registries Annual Meeting; June 2010.

Stanford RH, Gilsenan AW, Ziemiecki R, Zhou X, Lincourt WR, Ortega H. Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma. 2010 Apr 1;47(3):257-62. doi: 10.3109/02770900903584019

Lincourt W, Stanford RH, Gilsenan A, DiBenedetti D, Ortega H. Assessing primary care physician`s beliefs and attitudes of asthma exacerbation treatment and follow-up. Open Respir Med J. 2010 Feb 22;4:9-14.

Mintz M, Gilsenan AW, Bui CL, Ziemiecki R, Stanford RH, Lincourt W, Ortega H. Assessment of asthma control in primary care. Curr Med Res Opin. 2009 Oct 1;25(10):2523-31.

Gilsenan A, Stanford RH, Bui C, Ziemiecki RM, Ortega H. Predictors of uncontrolled asthma in adult and pediatric patients: results from the asthma control characteristics and prevalence survey study (ACCESS). Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2009. Providence, RI.

Gilsenan A, Andrews EB, Calingaert B, Crozier DA, Vanderpuije A. Evaluation of current risk evaluation and mitigation strategies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI.

Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica D, Andrews EB. The impact of patient access on post marketing drug safety studies using cancer registry data. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 14; 18(Suppl 1):S169. doi: 10.1002/pds.1806

Gilsenan AW, Andrews EB, Martin R, Midkiff KD. Charting a new course: the critical role of cancer registries in the science of drug safety. Poster presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.

Midkiff KD, Gilsenan AW, Martin RD, Andrews EB, Wu Y, Masica D. The new world in cancer surveillance: accommodating patient privacy and drug safety studies. Presented at the NAACCR; June 2009.

Midkiff KD, Martin RD, Gilsenan AW, Masica D, Andrews EB. New directions in using cancer registry data 5–year results from a patient drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.

Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica N, Andrews EB. Characteristics of patients in a post marketing osteosarcoma surveillance study. Presented at the 34th Meeting of the Scandinavian Sarcoma Group; May 2009.

Zhou X, Nonnemaker J, Sherrill B, Gilsenan AW, Coste F, West R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. Addict Behav. 2009 Apr 1;34(4):365-73.

Stanford RH, Gilsenan AW, Lincourt W, Lankevich C, Stempel DA, Ziemiecki RM, Ortega HG. Predictors of asthma control: results from the asthma control characteristics and prevalence survey study (ACCESS). Presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology; March 2009. Washington, DC.

Stanford RH, Gilsenan AW, Lincourt W, Lankevich C, Ortega HG. The effect of body mass index on asthma control: results from the asthma control characteristics and prevalence survey study (ACCESS). Presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology; March 2009. Washington, DC.

Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, Murray MD. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy. 2009 Mar;29(3):255-62.

Von Scheele BG, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D, Alvegård T. The European postmarketing adult osteosarcoma surveillance study characteristics of patients: a preliminary report. Acta Orthop. 2009;80:67-74.

Stanford RH, Gilsenan AW, Lincourt W, Lankevich C, Ortega H. Status of asthma control in primary care in the US: results from the asthma control characteristics and prevalence survey study (ACCESS). Presented at the American College of Asthma Allergy and Immunology Annual Meeting; November 2008.

Lincourt W, Stanford RH, Gilsenan AW, Lankevich C, Vanderpuije A, Ortega H. Status of asthma control in pediatric practices in the US: results from the asthma control characteristics and prevalence survey study (ACCESS). Poster presented at the American College of Nurse Practitioner Meeting; October 2008.

Gilsenan AW, Ladner A, Varas-Lorenzo C, Kold Olesen T, Karup C, Andrews EB. Incidence of cardiovascular and cerebrovascular events among men with prostate cancer. Poster presented at the 24th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 9, 2008. Copenhagen, Denmark.

Andrews EB, Irish WD, Gilsenan AW, Campbell WH. Evaluation of therapeutic risk management programs. In: Hartzema AG, Tilson HH, Arnold Chan K, editors. Pharmacoepidemiology and therapeutic risk management. 1st ed. Cincinnati: United States. Harvey Whitney Books; 2008. p.637-52.

Andrews EB, Gilsenan AW, Cook SF. Therapeutic risk management interventions: feasibility and effectiveness. In: Pharmacoepidemiology and therapeutic risk management. Cincinnati: United States. Harvey Whitney Books; 2008. p.613-33.

Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang A. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007 Sep 1;61(9):1437-45.

Midkiff K, Gilsenan A, Martin R, Masica DN, Andrews E. Characteristics of patients in a postmarketing osteosarcoma surveillance study. Poster presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2007. Quebec City, Canada.

Gilsenan AW, Midkiff K, Wu Y, Martin R, Masica DN, Andrews E. Factors associated with interview completion rates in a surveillance study of osteosarcoma and antecedent exposures. Poster presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2007. Quebec City, Canada.

Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 21, 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug 7; 16(Suppl 2):S55. doi: 10.1002/pds.1461

Martin RD, Gilsenan AW, Wu Y, Midkiff KD, Masica DN. Long-term post-marketing studies: flexibility, perseverance and patience. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.

Martin RD, Gilsenan AW, Midkiff KD, Wu Y, Andrews EB, Masica DN. Adult osteosarcoma surveillance study: results from a telephone survey with patients identified through central cancer registries. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.

Martin RD, Gilsenan AW, Von Scheele BG. International drug safety monitoring using population-based cancer registries. Poster presented at the North American Association of Central Cancer Registries; 2007.

Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Assessing the impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Poster presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2007.